← Back
$SYRE All transactions

Spyre Therapeutics, Inc.

▼ SELL 10b5-1 Plan

$ Value

$607K

Shares

12,344

Price

$49

Filed

Apr 3

Insider

Name

Turtle Cameron

Title

Chief Executive Officer

CIK

0001758363

Roles

Director Officer

Transaction Details

Transaction Date

2026-04-01

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

630,196

Footnotes

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.64 to $49.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. | Includes 116,168 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.64 to $50.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Filing Info

Accession No.

0001758363-26-000007

Form Type

4

Issuer CIK

0001636282

Turtle Cameron's History

Date Ticker Type Value
2026-04-01 SYRE $607K
2026-04-01 SYRE $133K
2026-03-23 DMRA A $0
2025-11-03 SYRE $651K
2025-11-03 SYRE $399K
2025-06-02 ORKA A $0

Other Insiders at SYRE (90d)

Insider Bought Sold Last
Turtle Cameron
Chief Executive Officer
$133K 2026-04-01
Burrows Scott L
Chief Financial Officer
$370K 2026-04-01
Sloan Sheldon
Chief Medical Officer
$398K 2026-04-01